News

AddToAny

Google+ Facebook Twitter Twitter

Vaccine to treat lung cancer

A first-of-its-kind treatment vaccine has moved into a phase I clinical trial for patients with non-small cell lung cancer.

AST-VAC2 is a collaboration agreement between Cancer Research UK and Asterias Biotherapeutics Inc.

Cancer Research UK will manage the initial clinical development of AST-VAC2, which is a promising immunotherapy candidate that is derived from a standardised human embryonic stem cell line.

If shown to be safe and effective, it’s hoped that AST-VAC2 could be used as an additional treatment for patients who no longer have advanced disease, but whose lung cancer is at high risk of coming back, or in combination with other treatments for patients with advanced disease.

Dr Nigel Blackburn, Cancer Research UK’s Director of drug Development, said: “This vaccine trial is a pioneering approach to improving treatment for lung cancer, the biggest cause of cancer death worldwide.

“By coupling our expertise with a leading biotechnology company, we’ve accelerated the development of this experimental treatment by years.”

Related Articles

The new dawn of immunotherapy

Steven Rosenberg made headlines around the globe for a breakthrough that could make immunotherapy a frontline cancer treatment.

Journal-based learning: iStock

July: Journal-based learning

Each article’s contents should be read, researched and understood, and you should then come to a decision on each question. The pass mark is 17 out of 20 questions answered correctly. JBL exercises may be completed at any time until the published deadline date. Please select your choice of correct answers and complete the exercises online at: www.ibms.org/cpd/jbl

Could bacteriophages replace antibiotics?

A small-scale preliminary trial concludes that bacteriophages could be a viable replacement for antibiotics in the future.

Microwave iStock

Antibiotic resistance and microwaves

Lecturer in Molecular Microbiology Tina Joshi looks at the detection of antimicrobial-resistant bacteria in the timeframe of a doctor’s appointment.

Top